## Montgomery County Interagency Commission on Homelessness

February 2, 2022



## AGENDA

- Welcome and Introductions of New Commissioners
- Review and Approve September Minutes
- COVID Update
- Highlights from the Annual Report
- Committee Updates
  - Outcomes and Improvement Committee
  - Allocation Committee
- Next Meeting: Wednesday, April 6, 2022, 3:00-5:00 pm




## COVID UPDATE

# COVID cases amongst the homeless population, mass testing, and vaccinations



### **COVID POSITIVES in the Homeless Continuum**



**COVID Trends** 

- Total of 405 Clients contracted COVID-19
- 95 Homeless Services Staff tested positive
- 7 COVID related deaths



## Testing and Vaccinations

Onsite testing at all congregate facilities continues

- Weekly PCR at transitional housing programs and family shelter
- Every other week testing at congregate permanent supportive housing programs
- Twice weekly rapid tests at large emergency shelters

#### Vaccinations

- Bi-Monthly at large sites
- About 40% shelter guests are vaccinated

## **Shelter Provider Experience**





## **COVID-19 Vaccine Participation Project**

## 2021





- Target PSH & RRH clients with vaccine education and information. ~ 46 clients living in scattered site locations
- 2. Coordinate essential supports, such as transportation (Contract Barwood / Regency for door-to-door transportation to vaccine appointments.)
- 3. Tracking of appointments and date each client received vaccine.
- 4. Revisit the participant list regularly. Maintain engagement with vaccine resistant clients.



|    | A           | В      | С      | D         | E          | F                        | G  | н                    | I              | J           | к           | L         | M       |
|----|-------------|--------|--------|-----------|------------|--------------------------|--|----------------------|----------------|-------------|-------------|-----------|---------|
| 1  |             | Client | Client | Client    |            |                          |  |                      |                |             |             |           |         |
|    | Piority     | ID     | First  | Last Name |            | _                        |  | Agree to             | - · · ·        | Appointment | Appointment | Fully     |         |
| 2  | group       |        | Name   |           | DOB        | Case manager             | Employment status and Medical conditions                               | vaccinate?           | Preregistered? | date 1      | date 2      | Vaccinate | Vaccine |
| 3  | 1B - Tier 1 |        |        |           | 8771945    | Stephani Schaper         |  |                      |                |             |             |           |         |
| 4  | 1B - Tier 1 |        |        |           | 8/13/1940  | Stephani Schaper         |  | missed<br>appointmen |                |             |             |           |         |
| 5  |             |        |        |           |            |                          |  |                      |                |             |             |           |         |
| 6  | 1B - Tier 2 |        |        |           |            |                          |  |                      |                |             |             |           |         |
| 7  | 1B - Tier 2 |        |        |           | 3/6/1968   | Nick Heynen              | grocery store employee, hypertension, smok                             | ina                  |                |             |             |           |         |
| 8  |             |        |        |           |            |                          |  |                      |                |             |             |           |         |
| 9  | 1C - Tier 1 |        |        |           | 7/8/1951   | Stephani Schaper         |  |                      |                |             |             |           |         |
| 10 | 1C - Tier 1 |        |        |           |            | Stephani Schaper         |  |                      |                |             |             |           |         |
| 11 | 1C - Tier 1 |        |        |           |            | Deborah Taylor           |  |                      |                |             |             |           |         |
| 12 | 1C - Tier 1 |        |        |           | 8/18/1955  | Claire Cohen             |  |                      |                |             |             |           |         |
| 13 | 1C - Tier 1 |        |        |           |            | Stephani Schaper         |  |                      |                |             |             |           |         |
| 14 | 1C - Tier 1 |        |        |           |            | Stephani Schaper         |  |                      |                |             |             |           |         |
| 15 | 1C - Tier 1 |        |        |           |            | Stephani Schaper         |  |                      |                |             |             |           |         |
| 16 |             |        |        |           |            |                          |  |                      |                |             |             |           |         |
| 17 | 1C - Tier 2 |        |        |           | 11/10/1963 | Claire Cohen             | asthma   |                      |                |             |             |           |         |
| 18 | 1C - Tier 2 |        |        |           | 3/27/1968  | Claire Cohen             | brain injury, heart condition  | skeptical            |                |             |             |           |         |
| 19 | 1C - Tier 2 |        |        |           | 11/2/1973  | Stephani Schaper         | smokes   |                      |                | received    | 11-Apr      |           | ?       |
| 20 | 1C - Tier 2 |        |        |           | 3/11/1989  | Mark Babiak              | congestive heart failure, kidney disease,                              | sarcoidosis          |                |             |             |           |         |
| 21 | 1C - Tier 2 |        |        |           | 3/9/1957   | Nick Heynen              | COPD, arthritis, hypertension, smoking,                                |                      |                |             |             |           |         |
| 22 | 1C - Tier 2 |        |        |           |            |                          | liver condition  |                      |                | received    | ?           |           | Moderna |
| 23 | 1C - Tier 2 |        |        |           | 3/14/1962  | Mark Babiak              | severe heart problems, asthma, autism                                  |                      |                |             |             |           |         |
| 24 | 1C - Tier 2 |        |        |           | 6/27/1957  | Nick Heynen              | hypertension, smoking  |                      |                |             |             |           |         |
| 25 | 1C - Tier 2 |        |        |           | 5/12/1977  | Debra Taylor             | hepatic steatosis, bipolar disorder,                                   |                      |                | 21-Mar      | 13-Apr      |           | Pfizer  |
| 26 | 1C - Tier 2 |        |        |           |            | Stephani Schaper         | previous cancer, bipolar   | more<br>research     |                |             |             |           |         |
| 27 | 1C - Tier 2 |        |        |           |            | Claire Cohen             | smokes   |                      |                |             |             |           |         |
| 28 | 1C - Tier 2 |        |        |           |            | Nick Heynen              | diabetes, pancreatitis   |                      |                | received    |             |           | ?       |
| 29 | 1C - Tier 2 |        |        |           |            | Stephani Schaper         | neuropathy and spinal stenosis, in                                     |                      |                |             |             |           |         |
| 30 | 1C - Tier 2 |        |        |           | 8/20/1963  | Nick Heynen              | diabetes, hypertension, PTSD,  |                      |                |             |             |           |         |
| 31 | 1C - Tier 2 |        |        |           | 11/30/1960 | Nick Heynen              | congestive heart failure, COPD, asthma,<br>emphysema, smoking, obesity |                      |                |             |             |           |         |
| 32 | 1C - Tier 2 |        |        |           | 1/3/1967   | Nick Heynen              | smoking, obesity, congesive heart                                      |                      |                |             |             |           |         |
| 33 | 1C - Tier 2 |        |        |           |            | Nick Heynen              | arthritis, schizoaffective disorder,<br>depression, smoking            |                      |                |             |             |           |         |
| 34 | 1C - Tier 2 |        |        |           | 4/2/1967   | Stephani Schaper         | brain tumor, seizures  |                      |                |             |             |           |         |
| 35 | 1C - Tier 2 |        |        |           |            | Mark Babiak              | ischemic heart disease, affective mood                                 |                      |                |             |             |           |         |
| 36 | 1C - Tier 2 |        |        |           |            | Nick Heynen              | smoking  |                      |                |             |             |           |         |
| 37 |             |        |        |           |            |                          |  |                      |                |             |             |           |         |
| 38 | 2A          |        |        |           | 8/29/1959  | Stephani Schaper         | depression   |                      |                |             |             |           |         |
| 39 | 2A          |        |        |           |            |                          | hearing impaired   |                      |                |             |             |           |         |
| 40 | 2A          |        |        |           |            | Stephani Schaper         |  |                      |                |             |             |           |         |
| 41 | 2A          |        |        |           |            |                          | unspecified disability   |                      |                |             |             |           |         |
| 42 |             |        |        |           |            |                          |  |                      |                |             |             |           |         |
| 43 | 3           |        |        |           | 9/8/1968   | Stephani Schaper         | denies mental health problems  |                      |                |             |             |           |         |
| 44 | 3           |        |        |           |            |                          |  |                      |                |             |             |           |         |
| 45 | 3           |        |        |           |            | Stephani Schaper         |  |                      |                |             |             |           |         |
| 46 | 3           |        |        |           | 2/26/1961  | Stenhani Scha <u>per</u> | bipolar schizophrenia  |                      |                |             |             |           |         |



#### <u>Vaccine Participation – Tracking Milestones</u>

<u>April 8, 2021</u> 9 of 46 clients = 19%

<u>May 10, 2021</u>

21 of 46 clients = 46%

<mark>July 31, 2021</mark>

<mark>27 of 46 clients = 59%</mark>





|          | А      | в             | С         | D                            | Е                      | F                     | G                     | н                  |                  |
|----------|--------|---------------|-----------|------------------------------|------------------------|-----------------------|-----------------------|--------------------|------------------|
| 1        | Client | Client        | Client    |                              |                        |                       |                       |                    |                  |
| 2        | ID     | First<br>Name | Last Name | Case manager                 | Agree to<br>vaccinate? | Appointment<br>date 1 | Appointment<br>date 2 | Fully<br>Vaccinate | Vaccine          |
| 3        |        |               |           | Stephani Schaper             |                        |                       |                       |                    |                  |
| 4        |        |               |           | Stephani Schaper             |                        |                       |                       |                    |                  |
| 5        |        |               |           | Stephani Schaper             |                        |                       |                       |                    |                  |
| 6        |        |               |           | Stephani Schaper             |                        |                       |                       |                    |                  |
| 7        |        |               |           | Claire Cohen                 | skeptical              |                       |                       |                    |                  |
| 8        |        |               |           | Stephani Schaper             |                        |                       |                       |                    |                  |
| 9        |        |               |           | Stephani Schaper             |                        |                       |                       |                    |                  |
| 10       |        |               |           | Stephani Schaper             | not sure               |                       |                       |                    |                  |
| 11       |        |               |           | Claire Cohen                 | skeptical              |                       |                       |                    |                  |
| 12       |        |               |           | Stephani Schaper             |                        | 14-Mar                | 11-Apr                |                    | Moderna          |
| 13       |        |               |           | Stephani Schaper             |                        | 31-Mar                | 23-Apr                |                    | Pfizer           |
| 14       |        |               |           | Stephani Schaper             |                        | 28-Apr                | 19-May                |                    | Pfizer           |
| 15       |        |               |           | Mark Babiak                  |                        | February              | March                 |                    | Moderna          |
| 16       |        |               |           | Mark Babiak                  |                        | April                 | 5-May                 |                    | ?                |
| 17       |        |               |           | Stephani Schaper             |                        | 8-Apr                 | 7-May                 |                    | Moderna          |
| 18       |        |               |           | Nick Heynen                  |                        | 26-Apr                | 24-May                |                    | Moderna          |
| 19       |        |               |           | Stephani Schaper             |                        | <u> </u>              |                       |                    | - DC             |
| 20       |        |               |           | Nick Heynen                  |                        | 2-Apr                 | 23-Apr                |                    | Pfizer           |
| 21       |        |               |           | Claire Cohen<br>Claire Cohen |                        |                       | 22.4                  |                    |                  |
| 22<br>23 |        |               |           | Claire Cohen                 |                        | received<br>9-Apr     | 23-Apr<br>n/a         |                    | Moderna<br>J&J   |
| 23       |        |               |           | Stephani Schaper             |                        | 12-Apr                | nla                   |                    |                  |
| 24       |        |               |           | Mark Babiak                  |                        | iz-Api                | nia                   |                    |                  |
| 26       |        |               |           | Stephani Schaper             |                        | March                 | nla                   |                    | J&J              |
| 27       |        |               |           | Claire Cohen                 |                        | received              | nla                   |                    | J&J              |
| 28       |        |               |           | Nick Heynen                  |                        | 22-Jun                |                       |                    |                  |
| 29       |        |               |           | Stephani Schaper             | wait longer            |                       |                       |                    |                  |
| 30       |        |               |           | Nick Heynen                  |                        |                       |                       |                    |                  |
| 31       |        |               |           | Stephani Schaper             |                        | 8-Apr                 | ?                     |                    |                  |
| 32       |        |               |           | Debra Taylor                 |                        | 21-Mar                | 13-Apr                |                    | Pfizer           |
| 33       |        |               |           | Stephani Schaper             | more<br>research       |                       |                       |                    |                  |
| 34       |        |               |           | Stephani Schaper             |                        | 1-Apr                 | ?                     |                    | Pfizer           |
| 35       |        |               |           | Claire Cohen                 | wait longer            |                       |                       |                    |                  |
| 36       |        |               |           | Stephani Schaper             |                        |                       |                       |                    |                  |
| 37       |        |               |           | Nick Heynen                  |                        | 15-Feb                | 25-May                |                    | J&J              |
| - 38     |        |               |           | Stephani Schaper             |                        | 8-Apr                 | nła                   |                    | J&J              |
| - 39     |        |               |           | Nick Heynen                  |                        |                       |                       |                    |                  |
| 40       |        |               |           | Nick Heynen                  |                        |                       |                       |                    |                  |
| 41       |        |               |           | Nick Heynen                  |                        |                       |                       |                    |                  |
| 42       |        |               |           | Nick Heynen                  |                        | 3-Jun                 | 24-Jun                |                    | Pfizer           |
| 43       |        |               |           | Stephani Schaper             |                        | 16-Apr                | 7-May                 |                    | Pfizer           |
| 44       |        |               |           | Stephani Schaper             |                        | 12-Apr                | nla                   |                    | J&J              |
| 45       |        |               |           | Stephani Schaper             |                        | 14-May                | 4-Jun                 |                    | Pfizer           |
| 46       |        |               |           | Mark Babiak                  |                        | 18-Mar                | 15-Apr<br>2           |                    | Moderna          |
| 47       |        |               |           | Mark Babiak                  |                        | 10-May                |                       |                    | b da al a sus al |
| 48       |        |               | 1         | Nick Heynen                  |                        | 26-Apr                | 24-May                |                    | Moderna          |



2021 Vaccine Participation Project Bethesda Cares Team Members

Deborah Taylor – Programs Director Stefani Schaper – HIP Service Coordinator Claire Cohen – HIP Service Coordinator Mark Babiak – Critical Time Intervention Specialist Nick Heynen – Veterans Supportive Housing Specialist Curtis Barton – Volunteer John Mendez – Executive Director



## CoC Response to COVID

# Short and Long-Term Program and Policy Changes and Recommendations



### **Permanent Changes to Shelter**



- New 200-Bed Men's Shelter
- All shelters will accommodate the need for social distancing
- Enhanced case management support
- Year-round bed capacity increases from 140 to 400



### New Approaches to Housing

#### Expansion of Rapid Rehousing

- <u>Temporary</u> ESG-CV funding added approximately 240 slots
- Included employment services

#### COVID Rent Relief Program – Rapid Resolution

- Provides short-term housing subsidy with no case management
- 311 households served from May 2020 November 2021
- 14% Rate of Return to Homelessness

#### **Emergency Housing Vouchers**

- 118 Permanent Housing Vouchers <u>non-transferrable</u>
- 20 dedicated to vulnerable adults experiencing homelessness
- 98 dedicated to Move-Up from permanent supportive housing and/or exit from rapid rehousing


#### Exit Bonus Program

- Provides \$5000 in direct cash assistance to exit homelessness
- 113 households served
- 24% Rate of Return to Homelessness

#### Improved Access to Services


Increased Access to Behavioral Health and Primary Care Services

- Funding through a one-time state grant
- Increased primary care services in shelter and through street outreach
- Added Peer Support in shelters
- Contracted with community psychiatrist to provide onsite services at shelter and through street outreach





### **Centralized Intake and Homeless Diversion**



Implemented Centralized Intake and Diversion for Adult Only households

- Used combination of temporary funding from federal and private grants
- Responded to 500 requests for shelter
- Provided \$300K in diversion grants

#### Limitations

- Not able to provide 24/7 access
- Inadequate staffing to provide continuing case management
- Need a single hotline for households seeking services



### **Medium and**

Long-Term

Challenges

Secure funding to continue COVID expansion of services


Develop a new approach to Eviction Prevention when federal funding is no longer available. The pre-pandemic annual budget for eviction prevention is \$4 million. To date, over \$69 million has been used to prevent more than 9000 evictions.



## Highlights from the 2021 Annual Report




## Veteran Homelessness




- Since January 2015, we have ended homelessness for 219 Veterans
- Functional zero is 6 Veterans, average # of Veterans experiencing homelessness each month is 11
- Discussion: Do we need to advocate for a new "functional zero"?



## Vulnerable Adult Only Households



#### 209 Vulnerable Adults Housed in the Last 2 Years



#### Monthly Average of 76 Vulnerable Adults



## Changes in Vulnerability

#### **Medical Conditions**

- 23% have untreated or under treated medical conditions (23% decrease from FY21)
- 4% have serious medical condition with no or sporadic treatment (75% decrease for FY21)

#### **Mental Health**

- 37% have untreated or under treated mental health challenges (14% decrease from FY21)
- 14% have serious mental illness that is not being treated or only sporadic treatment (52% decrease from FY21)

#### Substance Use

- 22% have untreated or under treated substance use disorders (15% decrease from FY21)
- 5% have untreated serious substance use disorders (55% decrease from FY21)

#### **Cognitive Deficits**

- 10% have untreated or under treated cognitive disorders (28% decrease from FY21)
- 2% have serious cognitive disorders with no or sporadic treatment (50% decrease from FY21)



**Opportunities for** Ending Homelessness for Vulnerable Adults


98 Permanent Supportive Housing slots available due to the EHV Move-Up program


Possible expansion of ACIS Medicaid pilot for supportive services

Discussion: Should we adjust our goals and specifically name vulnerable adults as a subpopulation?



### Families with Children







### Families with Children





### Funding and Legislative Priorities

#### **Funding Priorities**

- More Affordable Housing and Dedicated Units
- \$3m for County Rental Assistance Program
- \$2.4 m for Rapid Rehousing and employment services
- Development of deeply affordable living quarters

#### Legislative and Regulatory Changes

- Eviction Protections
- Resources for Human Rights Commission to investigate Fair Housing violations
- Changes to state commitment laws



### DISCUSSION

We can totally end homelessness for all but by when?

What are the lessons learned from COVID and what do we want to keep doing?

Is it time to revisit the Strategic Plan to End Homelessness?





## System Performance Goals



### Goal 1: Decrease the average length of homelessness

| FY 21 Data | FY 21 Projection | Difference | FY 22 Target |
|------------|------------------|------------|--------------|
| 108        | 141              | -33        | 120          |



# Goal 2: Maintain the % of households who return to homelessness within two years

| FY 21 Data | FY 21<br>Projection | Difference | FY 22<br>Target |
|------------|---------------------|------------|-----------------|
| 18%        | 15%                 | 3%         | 13%             |



## Goal 3: Decrease the number of people experiencing homelessness on any given night (Point in Time)

|             | FY 21<br>Data | FY 21<br>Projection | Difference | FY 22<br>Target |
|-------------|---------------|---------------------|------------|-----------------|
| Sheltered   | 509           | 509 (-10%)          | 0          | 433 (-15%)      |
| Unsheltered | 68            | 68 (-34%)           | 0          | 61 (-10%)       |



## Goal 4: Increase the number of adults who increase their total cash income while in permanent housing

| FY 21<br>Data | FY 21 Projection | Difference | FY 22 Target |
|---------------|------------------|------------|--------------|
| 37%           | 38%              | -1%        | 40%          |



### Goal 5: Decrease the number of first-time homeless

| FY 21 Data | FY 21<br>Projection | Difference | FY 22 Target |
|------------|---------------------|------------|--------------|
| 1258       | 1300 (-1%)          | -2%        | 1170 (-10%)  |



# Goal 6: Increase the number of households placed in permanent housing

| FY 21 Data | FY 21<br>Projection | Difference | FY 22 Target |
|------------|---------------------|------------|--------------|
| 610 (45%)  | 48%                 | -3%        | 55%          |



### Data Quality

|   | All ES, SH |        | All TH |        | All PSH, OPH | I      | All RRH |        | All SO |        |
|---|------------|--------|--------|--------|--------------|--------|---------|--------|--------|--------|
|   | FY2020     | FY2021 | FY2020 | FY2021 | FY2020       | FY2021 | FY2020  | FY2021 | FY2020 | FY2021 |
| Unduplicated<br>Persons Served                          | 2199       | 2035   | 144    | 154    | 2426         | 2440   | 712     | 899    | 416    | 321    |
| Total Leavers   | 1752       | 1562   | 97     | 99     | 219          | 204    | 216     | 369    | 257    | 189    |
| Destination of<br>Don't Know,<br>Refused, or<br>Missing | 324        | 49     | 6      | 0      | 4            | 0      | 3       | 0      | 55     | 52     |
| Destination Error<br>Rate                               | 18.49 %    | 3.14%  | 6.19%  | 0%     | 1.83%        | 0%     | 1.39%   | 0%     | 21.40% | 27.51% |

HMIS APR Data reported as of December 2021

## **Allocation Committee Report**





- Held organizational level feedback sessions with each applicant
  - Shared detailed feedback that impacted rankings
  - Opportunity or two-way feedback
  - Applicants highly engaged and feedback was well received
- Emphasis on NOFO Rankings vs performance scorecard
  - The goal is to rank programs for the purpose of allocating funding
  - Scoring must have differentiation; not everyone can be #1
  - The rank is a reflection of the application; not a report card on performance



## High Level Summary

- All programs had strengths
  - High bed utilization and clean audit reports were common
- Pandemic created challenges that impacted costs and efficiency
- Three main areas for rankings
  - HMIS Data continues to be incomplete or inaccurate in many cases
  - Application very little differentiation
  - Housing First and COVID addendums high variation in detail of responses
    - Integration of resident experience in planning/programming
    - Details on support of housing first
    - Details on COVID response
- May be more opportunity in the future to differentiate scoring for RRH vs PSH
  - RRH may have been disproportionately impacted in the rankings by the pandemic
- Noted differences to the mean on demographics of populations served
  - No one was penalized, but the committee did note where demographics were skewed



## Takeaways for Next Year

- Emphasize from the start the purpose for the rankings and why differentiation is critical to that process
  - Applicants impact their rankings by the thoroughness of their responses
- Encourage applicants to make sure their data is complete and accurate in HMIS
- Consider revising the scoring methodology to more accurately reflect evolving strategies and ensure rankings reflect funding priorities
- Consider revising the scoring methodology to make sure that program differences are accurately captured
- Continue to conduct feedback sessions

